文献速递冠心病

急性冠脉综合征口服P2Y12抑制剂疗效与安全性比较:12项随机试验52 816例患者的网络Meta分析

Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.
PubMed 文献 · Circulation · 2020-05-29

该网络Meta分析纳入12项随机对照试验共52 816例急性冠脉综合征患者,比较普拉格雷、替格瑞洛与氯吡格雷的疗效与安全性。与氯吡格雷相比,替格瑞洛显著降低心血管死亡和全因死亡,普拉格雷未显示显著死亡获益;两者均降低支架血栓但增加大出血。普拉格雷与替格瑞洛之间所有结局均无显著差异。

要点

  • 与氯吡格雷相比,替格瑞洛显著降低心血管死亡(HR 0.82)和全因死亡(HR 0.83)。
  • 普拉格雷与替格瑞洛均显著降低支架血栓风险,但均显著增加大出血。
  • 普拉格雷与替格瑞洛之间所有疗效与安全性结局均无显著差异。

核心结论

  • 与氯吡格雷相比,普拉格雷和替格瑞洛均减少缺血事件但增加出血,仅替格瑞洛观察到显著死亡下降。
  • 普拉格雷与替格瑞洛之间在全部探索结局上均无疗效与安全性差异。

研究设计与样本

  • 研究为网络Meta分析与直接配对比较分析,纳入12项随机对照试验,共52 816例急性冠脉综合征患者。
  • 研究已在PROSPERO注册,注册号为CRD42019155648。

主要发现

  • 与氯吡格雷相比,替格瑞洛显著降低心血管死亡(HR 0.82,95%CI 0.72-0.92)和全因死亡(HR 0.83,95%CI 0.75-0.92)。
  • 与氯吡格雷相比,普拉格雷未显著降低心血管死亡(HR 0.90,95%CI 0.80-1.01)和全因死亡(HR 0.92,95%CI 0.84-1.02)。
  • 普拉格雷与替格瑞洛之间死亡风险无显著差异(HR 1.10,95%CI 0.94-1.29;HR 1.12,95%CI 0.98-1.28)。
  • 与氯吡格雷相比,普拉格雷降低心肌梗死(HR 0.81,95%CI 0.67-0.98),替格瑞洛未显示风险降低(HR 0.97,95%CI 0.78-1.22),两者间差异无统计学意义。
  • 与氯吡格雷相比,替格瑞洛和普拉格雷均显著降低支架血栓风险(降幅28%-50%范围),但均显著增加大出血(普拉格雷HR 1.26,95%CI 1.01-1.56;替格瑞洛HR 1.27,95%CI 1.04-1.55)。

临床怎么用

  • 在急性冠脉综合征患者中,选择替格瑞洛或普拉格雷而非氯吡格雷可减少缺血事件,但需权衡大出血风险。
  • 替格瑞洛与普拉格雷之间疗效与安全性无显著差异,选择时可结合患者出血风险与临床情况个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New randomized, controlled trials have become available on oral P2Y12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials. METHODS: We performed a network meta-analysis and direct pairwise comparison analysis of efficacy and safety outcomes from 12 randomized controlled trials including a total of 52 816 patients with acute coronary syndrome. RESULTS: In comparison with clopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), whereas there was no statistically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.80-1.01] and HR, 0.92 [95% CI, 0.84-1.02], respectively). In comparison with each other, there were no significant differences in mortality (HR prasugrel versus ticagrelor, 1.10 [95% CI, 0.94-1.29] and 1.12 [95% CI, 0.98-1.28]). In comparison with clopidogrel, prasugrel reduced myocardial infarction (HR, 0.81 [95% CI, 0.67-0.98]), whereas ticagrelor showed no risk reduction (HR, 0.97 [95% CI, 0.78-1.22]). Differences between prasugrel and ticagrelor were not statistically significant. Stent thrombosis risk was significantly reduced by both ticagrelor and prasugrel versus clopidogrel (28%-50% range of reduction). In comparison with clopidogrel, both prasugrel (HR, 1.26 [95% CI, 1.01-1.56]) and ticagrelor (HR, 1.27 [95% CI, 1.04-1.55]) significantly increased major bleeding. There were no significant differences between prasugrel and ticagrelor for all outcomes explored. CONCLUSIONS: Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42019155648.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. Circulation. 2020. PMID: 32468837. doi:10.1161/CIRCULATIONAHA.120.046786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。